Clinical trial
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
NCT00748358
Study timeline
Study start (unknown)2008-03-01Date precision: month
Registry last updated2013-09-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostatic Neoplasmsunresolved
Neoplasms, Hormone-Dependentunresolved
Tumor Markers, Biologicalunresolved
Survival Rateunresolved
Disease-Free Survivalunresolved
Interventions
sunitinibDRUG · verified · RxNorm: sunitinib
Sponsors & collaborators
Assistance Publique - Hôpitaux de Parislead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00748358 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.